GLP-1, or glucagon-like peptide-1, plays a key role in glucose metabolism and appetite regulation in the body. The use of medications such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), that mimic the action of GLP-1, have recently gained prominence in healthcare settings because of their success in the treatment of type 2 diabetes and the management of weight-loss.
In this special extended Chemistry World webinar, you will have the chance to connect with three expert scientists working on GLP-1 science spanning the entire history of its development whilst also investigating its future applications for the management of a whole host of other diseases. You will have a chance to hear from:
Svetlana Mojsov who is a pioneer in the study of this crucial hormone and whose research has been instrumental in the development of GLP-1 receptor agonists
Richard DiMarchi whose academic expertise and work within the pharmaceutical industry has played a pivotal role in advancing both the scientific understanding and clinical application of GLP-1 therapies
Stefan Trapp who leads a research group that investigates the physiological functions of GLP-1 and its potential as a therapeutic target for metabolic diseases
Don’t miss this opportunity to explore the science of GLP-1 medications and their significant impact on health.
Speakers
Svetlana Mojsov
Svetlana Mojsov is a research associate professor at Rockefeller University, US. She was born in Skopje, the capital of Northern Macedonia, former Yugoslavia. Mojsov has a degree in physical chemistry from the University of Belgrade, Serbia and obtained a PhD from Rockefeller University, US. From 1983 Mojsov developed an independent research programme at the Endocrine Unit at the Massachusetts General Hospital, US leading to the discovery that GLP-1(7-37) is an incretin with therapeutic potential for treatment of diabetes. She is a co-inventor on patents for the use of GLP-1(7-37) as treatment of type 2 diabetes. Mojsov is a recipient of numerous awards, including the 2023 Vin Future Prize, 2024 Pearl Meister Greengard Award, 2024 Tang Foundation Prize, 2024 Princess of Asturias Prize and 2024 Lasker-DeBakey Clinical Medical Research Award.
Richard DiMarchi
Richard DiMarchi is a distinguished professor of chemistry and Gill Chair at Indiana University, US. He is a member of the National Academy of Medicine and the National Inventors Hall of Fame. He was group vice president at Eli Lilly and later at Novo Nordisk, and recognised for discovery and development of Humalog, rGlucagon, and Forteo. His academic research has broadened the understanding of glucagon physiology and the discovery of single molecule multimode agonists for the treatment of diabetes and obesity.
Stefan Trapp
Stefan Trapp is professor of autonomic neuroscience and metabolic disease at UCL, UK. He obtained his PhD from the University of Göttingen, Germany, before moving to the University of Oxford, UK. In 2003, Stefan established his own laboratory at Imperial College London, UK with seminal work on brainstem glucosensing. In 2013 Stefan moved to UCL, UK and founded the Centre for Cardiovascular and Metabolic Neuroscience with professor Alexander Gourine. For the past decade he has been working on the brain circuitry controlling energy balance. His work has spearheaded the investigation of brain-produced GLP-1 and its role on the regulation of food intake. A core interest of his research group is to unravel the physiology that underpins the clinical success of GLP-1-based therapies in metabolic disease and beyond.
No comments yet